ArticleExperimental and therapeutic medicine2018
Development of zoledronic acid functionalized hydroxyapatite loaded polymeric nanoparticles for the treatment of osteoporosis.
Article in Experimental and therapeutic medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 24 citations in OpenAlex.
- Double-edged-sword effect of bisphosphonates on the osteogenic differentiation of human periodontal ligament stem cells.Frontiers in pharmacology · 2026Article
- Zoledronic acid-loaded HAp-SiOTurkish journal of chemistry · 2026Article
- Injectable carboxymethyl chitosan/oxidized dextran hydrogels containing zoledronic acid modified strontium hydroxyapatite nanoparticles.RSC advances · 2025Article
- Functional hydrogel empowering 3D printing titanium alloys.Materials today. Bio · 2025Review
- Drug Delivery and Therapy Strategies for Osteoporosis Intervention.Molecules (Basel, Switzerland) · 2023Review
- Article
- Nanomaterial-assisted theranosis of bone diseases.Bioactive materials · 2023Review
- The Combined Anti-Tumor Efficacy of Bioactive Hydroxyapatite Nanoparticles Loaded with Altretamine.Pharmaceutics · 2023Article
- Biomimetic hydroxyapatite nanocrystals are an active carrier forInternational journal of nanomedicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study formulated a hydroxyapatite (HA)-coated lipid nanoparticle loaded with zoledronic acid to treat patients with osteoporosis (OP). HA-coated zoledronic acid loaded lipid bilayer nanoparticles (HZL NPs) were prepared using methods of extrusion and precipitation. Nanosized particles were prepared with the aim of increasing gradual and prolonged drug release and inducing toxicity of osteoblasts. Cellular morphology was investigated by scanning electron microscopy, which revealed clear spherical shaped NPs ~200 nm in size that could treat osteopores in the bone. In addition, a typical biphasic release pattern was observed that could be attributed to the presence of drug on the outer surface as well as on the inner core of the NPs. There was sustained release behavior [38.17±2.12% (pH 7.4) and 64.2±3.75% (pH 5) at 48 h] of the drug that maintained the drug reservoir effect at the bone site. Furthermore, HZL NPs increased the cytotoxicity of HFOb 1.19 cells and increased the proportion of cells in the early (18.1±12.4%), late (28.7±3.7%) and necrotic (67.5±1.2%) phases of apoptosis. Most importantly, HZL in the lipid nanoparticle exhibited a strong affinity towards HA, further enhancing its efficacy in the treatment of OP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.